Active Biotech Investor Relations Material

Active Biotech AB is a Swedish biotechnology company focused on developing treatments for cancer and inflammatory diseases. Its key projects include Tasquinimod, an immunomodulatory molecule in clinical trials for multiple myeloma and myelofibrosis, and Laquinimod, aimed at treating inflammatory eye disorders like uveitis. Additionally, Naptumomab, an antibody-based immunotherapy, is being tested in combination with other treatments for solid tumors, including non-small cell lung cancer. The company is headquartered in Lund, Sweden, and is listed on the Nasdaq Stockholm.